Abstract
BackgroundAngiosarcomas (AS) have poor prognosis and often metastasize to distant sites. The potential predictors of metastatic angiosarcomas (MAS) have not been extensively investigated. The main objective of this study was to identify survival predictors of MAS.MethodsSurveillance, Epidemiology, and End Results (SEER) datasets were used to identify patients with MAS from 2010 to 2016. Risk predictors were determined with the aid of Kaplan-Meier and Cox regression model analyses.ResultsA total of 284 MAS patients met the study entry criteria. Among these, 121 patients (42.6%) were diagnosed with metastasis in bone, 26 in brain (9.2%), 86 in liver (30.3%) and 171 in lung (60.2%). Overall, 96 patients (33.8%) had two or more metastatic sites. The 1- and 3-year overall survival (OS) rates were 20.8 and 3.8% while 1- and 3-year cancer-specific survival (CSS) rates were 22.0 and 5.2%, respectively. Cox regression analysis revealed chemotherapy, radiation treatment (RT) and tumor size ≤10 cm as independent favorable predictors of OS. In terms of CSS, tumor grade IV, tumor size > 10 cm and absence of chemotherapy were independent adverse predictors. Surgery did not prolong survival outcomes (both OS and CSS) in the current cohort.ConclusionMAS is associated with extremely poor survival. Chemotherapy, RT, and tumor size are independent predictors of OS. Chemotherapy and tumor size are independent prognostic factors of CSS. Chemotherapy is therefore recommended as the preferred treatment option for MAS patients.
Highlights
Angiosarcomas (AS) have poor prognosis and often metastasize to distant sites
Patients and tumor characteristics From 2010 to 2016, 284 patients with metastatic angiosarcomas (MAS) were identified from the SEER database
A total of 253 (89.1%) deaths were recorded, 180 of which were attributed to MAS-related mortality
Summary
Angiosarcomas (AS) have poor prognosis and often metastasize to distant sites. Angiosarcomas (AS) are rare, highly malignant softtissue sarcomas of vascular or lymphatic origin, which account for approximately 1–2% of all soft tissue sarcomas [1, 2]. These sarcomas can develop in any anatomic location of the body [1], frequently manifesting as cutaneous disease in elderly men [3]. Metastatic angiosarcomas (MAS) patients present significantly shorter median OS (3 months) [11], succumbing to metastatic disease [12]. We have conducted a retrospective population-based cohort study on patients selected from the SEER database, with a view to delineating the predictors of MAS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
